Article
Multidisciplinary Sciences
Pandiyan Amuthavalli, Jiang-Shiou Hwang, Hans-Uwe Dahms, Lan Wang, Jagannathan Anitha, Murugan Vasanthakumaran, Arumugam Dhanesh Gandhi, Kadarkarai Murugan, Jayapal Subramaniam, Manickam Paulpandi, Balamurugan Chandramohan, Shivangi Singh
Summary: The study demonstrates that ZnO nanoparticles synthesized using Lawsonia inermis L. are highly toxic against Anopheles stephensi while not affecting the predation efficiency of fish and copepod.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Khanh T. Do, Laura Quan Man Chow, Karen Reckamp, Rachel E. Sanborn, Howard Burris, Francisco Robert, D. Ross Camidge, Conor E. Steuer, John H. Strickler, Amy Weise, Jennifer M. Specht, Martin Gutierrez, Peter Haughney, Shawna Hengel, Christina Louise Derleth, Timothy A. Yap
Summary: SGN-2FF, a potent small-molecule inhibitor of glycoprotein fucosylation, demonstrated dose-proportional pharmacokinetics, evidence of pharmacodynamic target inhibition of glycoprotein fucosylation, and preliminary antitumor activity in advanced solid tumors. However, it was associated with thromboembolic events that led to study termination.
Article
Chemistry, Multidisciplinary
Nesreen S. Haiba, Hosam H. Khalil, Ahmed Bergas, Marwa M. Abu-Serie, Sherine N. Khattab, Mohamed Teleb
Summary: In this study, a dendrimeric architecture based on s-triazine was developed, which not only had tumor targeting ability but also could inhibit MMP-9 to halt cancer progression. The synthesized molecule demonstrated significant activity in inhibiting cancer cell growth and migration.
Article
Chemistry, Multidisciplinary
Nesreen S. Haiba, Hosam H. Khalil, Ahmed Bergas, Marwa M. Abu-Serie, Sherine N. Khattab, Mohamed Teleb
Summary: This study developed a new dendrimeric architecture that can target tumors and inhibit MMP-9, offering a potential treatment for cancer. Experimental results showed that one of the synthesized compounds exhibited high activity and safety against cancer cells. The compound functions by binding to the Zn of the active site of MMP-9 and exerting multiple inhibitory effects on cancer cells.
Article
Pharmacology & Pharmacy
Yoshitsugu Hino, Miu Okada, Christine Erikstrup Hallgreen, Marie Louise De Bruin, Randell E. Doty, Naoki Matsumaru, Katsura Tsukamoto
Summary: A cancer diagnosis is devastating and the demand for innovative anticancer drugs is high worldwide. This study focused on the development of first-in-class (FIC) anticancer drugs in the US, EU, and Japan. The approval time for FIC anticancer drugs was significantly longer in Japan compared to the US and EU. There were substantial lags in submission and approval between Japan and the US/EU, highlighting the need for improved international cooperation to reduce these drug lags.
BIOLOGICAL & PHARMACEUTICAL BULLETIN
(2023)
Article
Urology & Nephrology
Matteo Santoni, Francesco Massari, Sergio Bracarda, Enrique Grande, Marc R. Matrana, Mimma Rizzo, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Lorena Incorvaia, Angelo Martignetti, Javier Molina-Cerrillo, Veronica Mollica, Alessandro Rizzo, Nicola Battelli
Summary: Cabozantinib is an effective second-line treatment option for patients with primary refractory metastatic renal cell carcinoma (mRCC), regardless of whether first-line therapy is immune-based combination therapy or tyrosine kinase inhibitors.
EUROPEAN UROLOGY FOCUS
(2022)
Article
Chemistry, Medicinal
Georgiana Negru (Apostol), Alina Ghinet, Elena Bicu
Summary: This study describes the synthesis and evaluation of new hydrazones with quinoline, pyridine, benzothiazole, and imidazole moieties for their cytotoxic potential against 60 cancer cell lines. The 7-chloroquinolinehydrazones were found to be the most active compounds, exhibiting good cytotoxic activity on a large panel of cell lines from various tumor types. This study provides valuable insights into the structure-activity relationships of these experimental antitumor compounds.
Article
Oncology
A. Spreaflco, A. A. Heirali, D. V. Araujo, T. J. Tan, M. Oliva, P. H. H. Schneeberger, B. Chen, M. K. Wong, L. -A. Stayner, A. R. Hansen, S. D. Saibil, B. X. Wang, K. Cochrane, K. Sherriff, E. Allen-Vercoe, W. Xu, L. L. Siu, B. Coburn
Summary: This study evaluated the safety, tolerability, and ecological responses of an orally administered 30-species microbial consortium (MET4) as an alternative to immune checkpoint inhibitor (ICI) treatment. The trial achieved its primary safety and tolerability outcomes, and observed variations in MET4 species relative abundance after administration. The results justify further development of microbial consortia as a therapeutic co-intervention for ICI treatment in cancer.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Maribel G. Vallespi, Braulio Mestre, Maria A. Marrero, Rolando Uranga, Diana Rey, Martha Lugiollo, Mircea Betancourt, Kirenia Silva, Danay Corrales, Yanet Lamadrid, Yamilka Rodriguez, Anaelys Maceo, Pedro P. Chaviano, Gilda Lemos, Ania Cabrales, Freya M. Freyre, Hector Santana, Hilda E. Garay, Brizaida Oliva, Julio R. Fernandez
Summary: CIGB-552 is a synthetic peptide that upregulates COMMD1 protein levels, showing clinical benefits in patients with advanced tumors. The maximum tolerated dose was defined as 4.7 mg, with dose-limiting toxicity observed at 7.0 mg. Seven patients had significant changes in CD4/CD8 ratio in response to treatment.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Pierfrancesco Tassone, Maria Teresa Di Martino, Mariamena Arbitrio, Lucia Fiorillo, Nicoletta Staropoli, Domenico Ciliberto, Alessia Cordua, Francesca Scionti, Bernardo Bertucci, Angela Salvino, Mariangela Lopreiato, Fredrik Thunarf, Onofrio Cuomo, Maria Cristina Zito, Maria Rosanna De Fina, Amelia Brescia, Simona Gualtieri, Caterina Riillo, Francesco Manti, Daniele Caracciolo, Vito Barbieri, Eugenio Donato Di Paola, Adele Emanuela Di Francesco, Pierosandro Tagliaferri
Summary: We developed an LNA-i-miR-221 inhibitor that downregulated miR-221 and showed anti-tumor activity in mice. The drug was well tolerated in patients and the recommended phase II dose was determined to be 5 mg/kg.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Oncology
In Sil Choi, Ki Hwan Kim, Ju Hyun Lee, Koung Jin Suh, Ji-Won Kim, Jin Hyun Park, Yu Jung Kim, Jin-Soo Kim, Jee Hyun Kim, Jin Won Kim
Summary: The study found that in the second-line treatment of biliary tract cancer, irinotecan/5-fluorouracil (mFOLFIRI) was not superior to oxaliplatin/5-fluorouracil (mFOLFOX), but both showed comparable efficacy and tolerability. Adverse events differed between the two treatment arms.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Sheena Bhalla, Farjana J. Fattah, Chul Ahn, Jessica Williams, Alyssa Macchiaroli, Jonathan Padro, Meredith Pogue, Jonathan E. Dowell, William C. Putnam, Nigel McCracken, David Micklem, Rolf A. Brekken, David E. Gerber
Summary: This study evaluated the efficacy and safety of bemcentinib in combination with docetaxel in advanced NSCLC patients. The results showed that bemcentinib plus docetaxel could inhibit tumor growth and produce partial responses in some patients.
Article
Oncology
Todd M. Bauer, Kathleen N. Moore, Janet S. Rader, Fiona Simpkins, Alain C. Mita, J. Thaddeus Beck, Lowell Hart, Quincy Chu, Amit Oza, Anna V. Tinker, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh Mugundu, Suzanne Jenkins, Juliann Chmielecki, Suzanne Jones, David Spigel, Siqing Fu
Summary: This study evaluated the safety and efficacy of adavosertib monotherapy in patients with different tumor types and molecular profiles. The results showed that adavosertib monotherapy has some antitumor activity in patients with advanced solid tumors.
Article
Oncology
Jean-Bernard Auliac, Isabelle Monnet, Acya Bizieux, Laurent Greillier, Margaux Geier, Lionel Falchero, Gwenaelle Le Garff, Regine Lamy, Florian Guisier, Charles Ricordel, Christos Chouaid, Alain Vergnenegre
Summary: Although the predefined minimal efficacy was not met, some patients with advanced NsqNSCLC refractory to first-line platin-based chemotherapy appeared to benefit from the nintedanib-docetaxel combination therapy.
